Followers | 818 |
Posts | 31469 |
Boards Moderated | 6 |
Alias Born | 03/22/2016 |
![](https://investorshub.advfn.com/uicon/558887.png?cb=1721046880)
Thursday, May 02, 2024 9:35:21 AM
Recent ALLR News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/21/2024 08:55:50 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 09:24:15 PM
- Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting • GlobeNewswire Inc. • 07/26/2024 01:00:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 07/26/2024 10:04:13 AM
- Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares • GlobeNewswire Inc. • 07/24/2024 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/23/2024 08:05:17 PM
- Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives • GlobeNewswire Inc. • 07/22/2024 10:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/22/2024 10:03:17 AM
- Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 12:54:31 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 05/24/2024 12:55:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/21/2024 12:15:26 PM
- Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement • GlobeNewswire Inc. • 05/20/2024 12:00:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/17/2024 08:08:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 01:15:10 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 08:45:38 PM
- Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Balances • GlobeNewswire Inc. • 05/14/2024 08:01:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/09/2024 03:21:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/09/2024 01:47:15 PM
- Form RW - Registration Withdrawal Request • Edgar (US Regulatory) • 05/08/2024 08:05:18 PM
- Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock • GlobeNewswire Inc. • 05/07/2024 01:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2024 01:29:16 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 05/06/2024 01:13:42 PM
- Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1 • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
FEATURED Element79 Gold Corp Provides Update on Nevada Portfolio • Aug 23, 2024 8:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Maybacks Adds Award Winning Show to Its Lineup Discusses Maybacks Opportunity • AHRO • Aug 22, 2024 11:30 AM
North Bay Resources Announces First Gold Concentrate at Mt. Vernon Gold Mine, Assays 12 oz/ton Gold, 17.5 oz/ton Platinum, and 8 oz./ton Silver, Sierra County, California • NBRI • Aug 22, 2024 10:28 AM
All Things Mobile Analytic, Inc. Reports Major Growth with Over $11 Million in Revenue • ATMH • Aug 22, 2024 7:19 AM
Unitronix Announces Strategic Entry into Cryptocurrency Space • UTRX • Aug 21, 2024 10:00 AM